CTOs on the Move

Pattern Bioscience

www.pattern.bio

 
Pattern is building a dream team of scientists and visionaries dedicated to addressing this global problem with faster, smarter diagnostics for more precise treatment.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.pattern.bio
  • 9430 Research Blvd Suite II-340
    Austin, TX USA 78759
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Pattern Bioscience raised $21.9M on 02/05/2020

Similar Companies

Nanostics

Nanostics is a precision health company focused on the development and commercialization of novel, non-invasive diagnostic tests for cancer and other diseases. Their core technology is an advanced liquid biopsy platform that can accurately diagnose can...

Inari

Inari embraces diversity in every aspect of our business to drive innovation and help build a new food system. Our technology matches the complexity of nature to transform seed using predictive design and multiplex gene editing – unlocking the full potential through our SEEDesign™ platform. The result is step-change products that lead to more productive acres and a more sustainable future for the food system.

Lentigen Corporation

Lentigen Corporation is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Deepcell

Our mission is to enable novel biological insights at the single-cell level for improved diagnosis and treatment of disease.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.